HMG vs LGD-4033
Extensively Studied vs Moderate Research
monitor Mechanism-based · 51% Both HMG and LGD-4033 can elevate estrogen. Combined estrogenic load increases risk of gynecomastia, water retention, and mood changes. Monitor estradiol levels and consider AI if needed.
Molecular Data
HMG LGD-4033
Weight — 338.25 Da
Half-life ~32 hours (FSH component: 39-54 hours) ~24-36 hours
Type Gonadotropin mixture Nonsteroidal selective androgen receptor modulator (C14H12F6N2O)
Key Benefits
HMG
01 FDA-approved for fertility treatment
02 Stimulates ovarian follicle development
03 Contains both FSH and LH naturally
04 Promotes spermatogenesis in men
05 Cost-effective alternative to recombinant FSH
06 LH activity may improve fertilization rates
07 Long clinical track record
08 Lower OHSS incidence with HP-hMG
LGD-4033
01 Strongest SARM for lean muscle mass accrual, with clinical trial data supporting dose-dependent increases in lean body mass
02 Tissue-selective action with minimal stimulation of the prostate and other androgen-sensitive tissues
03 Clinical evidence of improved physical function (leg press strength, stair-climbing speed) in hip fracture patients
04 No aromatization to estrogen (no estrogen-related water retention or gynecomastia at the receptor level)
05 No conversion to DHT (reduced risk of androgenic hair loss and prostate stimulation compared to testosterone)
06 Convenient once-daily oral dosing due to 24-36 hour half-life
07 Phase 2 clinical data available, providing a stronger evidence base than most other SARMs
Dosing Protocols
HMG
75-150 IU for ovulation induction; 150-300 IU for IVF / Daily during stimulation phase (7-12 days)
Ovulation induction 75-150 IU Daily
IVF stimulation 150-300 IU Daily for 7-12 days
Male fertility 75-150 IU 2-3x weekly
LGD-4033
5-10 mg/day / Once daily (oral)
Side Effects
HMG
Injection site reactions
Abdominal discomfort
Ovarian enlargement
Mood changes
Headache
LGD-4033
Testosterone suppression (dose-dependent; more suppressive than Ostarine at equivalent doses, occurs in most users by week 4-6)
Water retention (non-estrogenic mechanism, typically mild to moderate, contributes to scale weight increase)
HDL cholesterol reduction (dose-dependent lipid impact observed in clinical trials)
Headaches (most common in the first 1-2 weeks, usually transient)
Fatigue or lethargy (related to testosterone suppression, typically becomes noticeable mid-cycle)
Reduced libido (related to HPG axis suppression, severity varies by dose and individual)
Contraindications
Primary ovarian failure
Uncontrolled thyroid or adrenal dysfunction
Sex hormone-dependent tumors
Abnormal uterine bleeding of unknown cause
Ovarian cysts (not due to PCOS)
Pregnancy
Pre-existing liver disease or elevated liver enzymes at baseline
Hormone-sensitive cancers (prostate cancer or other androgen-driven malignancies)
Pregnancy or potential pregnancy (teratogenic risk from androgen receptor agonism)
Breastfeeding
Age under 25 (incomplete endocrine system maturation and higher risk of HPG axis disruption)
Concurrent use of hepatotoxic medications without medical supervision
Known cardiovascular disease (insufficient long-term safety data for this population)
History of significant lipid abnormalities (LGD-4033 suppresses HDL)
Research Evidence
HMG LGD-4033
Status Extensively Studied Moderate Research
References 4 studies 5 studies
Latest — 2018
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.